The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring

Nanda Kerkar, Raffaella A. Morotti, Rebecca P. Madan, Benjamin Shneider, Betsy Herold, Christina Dugan, Tamir Miloh, Ilhan Karabicak, James A. Strauchen, Sukru Emre

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Pediatric PTLD is often associated with primary EBV infection and immunosuppression. The aim was to retrospectively review the spectrum of histologically documented PTLD for two time intervals differentiated by changes in use of molecular EBV monitoring. Eleven of 146 patients (7.5%) in 2001-2005 (Era A) and 10 of 92 (10.9%) in 1993-1997 (Era B) were diagnosed with PTLD. The median age at liver transplantation (0.8 and 0.9 yr, respectively) and the median duration between liver transplant and diagnosis of PTLD (0.6 and 0.7 yr, respectively) were similar in both eras. However, patients in Era A presented with significantly less advanced histological disease compared to patients in Era B (p = 0.03). Specifically, nine patients (82%) in Era A had Pl hyperplasia/polymorphic PTLD, whereas in Era B, six had advanced histological disease (five monomorphic and one unclassified). Three transplant recipients in Era B died secondary to PTLD, whereas there were no PTLD-related deaths in Era A (p = 0.03). Heightened awareness of risk for PTLD, alterations in baseline immunosuppression regimens, implementation of molecular EBV monitoring, pre-emptive reduction in immunosuppression and improved therapeutic options may have all contributed to a milder PTLD phenotype and improved clinical outcomes.

Original languageEnglish (US)
Pages (from-to)504-511
Number of pages8
JournalPediatric Transplantation
Volume14
Issue number4
DOIs
StatePublished - 2010

Fingerprint

Human Herpesvirus 4
Immunosuppression
Transplants
Epstein-Barr Virus Infections
Liver Transplantation
Hyperplasia
Pediatrics
Phenotype
Liver
Therapeutics

Keywords

  • Epstein-Barr virus
  • Histology
  • Immunosuppression
  • Liver transplantation
  • Lymphoproliferative disease
  • Outcome

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation
  • Medicine(all)

Cite this

The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring. / Kerkar, Nanda; Morotti, Raffaella A.; Madan, Rebecca P.; Shneider, Benjamin; Herold, Betsy; Dugan, Christina; Miloh, Tamir; Karabicak, Ilhan; Strauchen, James A.; Emre, Sukru.

In: Pediatric Transplantation, Vol. 14, No. 4, 2010, p. 504-511.

Research output: Contribution to journalArticle

Kerkar, N, Morotti, RA, Madan, RP, Shneider, B, Herold, B, Dugan, C, Miloh, T, Karabicak, I, Strauchen, JA & Emre, S 2010, 'The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring', Pediatric Transplantation, vol. 14, no. 4, pp. 504-511. https://doi.org/10.1111/j.1399-3046.2009.01258.x
Kerkar, Nanda ; Morotti, Raffaella A. ; Madan, Rebecca P. ; Shneider, Benjamin ; Herold, Betsy ; Dugan, Christina ; Miloh, Tamir ; Karabicak, Ilhan ; Strauchen, James A. ; Emre, Sukru. / The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring. In: Pediatric Transplantation. 2010 ; Vol. 14, No. 4. pp. 504-511.
@article{13452e183ef941fb96839d4785129ec4,
title = "The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring",
abstract = "Pediatric PTLD is often associated with primary EBV infection and immunosuppression. The aim was to retrospectively review the spectrum of histologically documented PTLD for two time intervals differentiated by changes in use of molecular EBV monitoring. Eleven of 146 patients (7.5{\%}) in 2001-2005 (Era A) and 10 of 92 (10.9{\%}) in 1993-1997 (Era B) were diagnosed with PTLD. The median age at liver transplantation (0.8 and 0.9 yr, respectively) and the median duration between liver transplant and diagnosis of PTLD (0.6 and 0.7 yr, respectively) were similar in both eras. However, patients in Era A presented with significantly less advanced histological disease compared to patients in Era B (p = 0.03). Specifically, nine patients (82{\%}) in Era A had Pl hyperplasia/polymorphic PTLD, whereas in Era B, six had advanced histological disease (five monomorphic and one unclassified). Three transplant recipients in Era B died secondary to PTLD, whereas there were no PTLD-related deaths in Era A (p = 0.03). Heightened awareness of risk for PTLD, alterations in baseline immunosuppression regimens, implementation of molecular EBV monitoring, pre-emptive reduction in immunosuppression and improved therapeutic options may have all contributed to a milder PTLD phenotype and improved clinical outcomes.",
keywords = "Epstein-Barr virus, Histology, Immunosuppression, Liver transplantation, Lymphoproliferative disease, Outcome",
author = "Nanda Kerkar and Morotti, {Raffaella A.} and Madan, {Rebecca P.} and Benjamin Shneider and Betsy Herold and Christina Dugan and Tamir Miloh and Ilhan Karabicak and Strauchen, {James A.} and Sukru Emre",
year = "2010",
doi = "10.1111/j.1399-3046.2009.01258.x",
language = "English (US)",
volume = "14",
pages = "504--511",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring

AU - Kerkar, Nanda

AU - Morotti, Raffaella A.

AU - Madan, Rebecca P.

AU - Shneider, Benjamin

AU - Herold, Betsy

AU - Dugan, Christina

AU - Miloh, Tamir

AU - Karabicak, Ilhan

AU - Strauchen, James A.

AU - Emre, Sukru

PY - 2010

Y1 - 2010

N2 - Pediatric PTLD is often associated with primary EBV infection and immunosuppression. The aim was to retrospectively review the spectrum of histologically documented PTLD for two time intervals differentiated by changes in use of molecular EBV monitoring. Eleven of 146 patients (7.5%) in 2001-2005 (Era A) and 10 of 92 (10.9%) in 1993-1997 (Era B) were diagnosed with PTLD. The median age at liver transplantation (0.8 and 0.9 yr, respectively) and the median duration between liver transplant and diagnosis of PTLD (0.6 and 0.7 yr, respectively) were similar in both eras. However, patients in Era A presented with significantly less advanced histological disease compared to patients in Era B (p = 0.03). Specifically, nine patients (82%) in Era A had Pl hyperplasia/polymorphic PTLD, whereas in Era B, six had advanced histological disease (five monomorphic and one unclassified). Three transplant recipients in Era B died secondary to PTLD, whereas there were no PTLD-related deaths in Era A (p = 0.03). Heightened awareness of risk for PTLD, alterations in baseline immunosuppression regimens, implementation of molecular EBV monitoring, pre-emptive reduction in immunosuppression and improved therapeutic options may have all contributed to a milder PTLD phenotype and improved clinical outcomes.

AB - Pediatric PTLD is often associated with primary EBV infection and immunosuppression. The aim was to retrospectively review the spectrum of histologically documented PTLD for two time intervals differentiated by changes in use of molecular EBV monitoring. Eleven of 146 patients (7.5%) in 2001-2005 (Era A) and 10 of 92 (10.9%) in 1993-1997 (Era B) were diagnosed with PTLD. The median age at liver transplantation (0.8 and 0.9 yr, respectively) and the median duration between liver transplant and diagnosis of PTLD (0.6 and 0.7 yr, respectively) were similar in both eras. However, patients in Era A presented with significantly less advanced histological disease compared to patients in Era B (p = 0.03). Specifically, nine patients (82%) in Era A had Pl hyperplasia/polymorphic PTLD, whereas in Era B, six had advanced histological disease (five monomorphic and one unclassified). Three transplant recipients in Era B died secondary to PTLD, whereas there were no PTLD-related deaths in Era A (p = 0.03). Heightened awareness of risk for PTLD, alterations in baseline immunosuppression regimens, implementation of molecular EBV monitoring, pre-emptive reduction in immunosuppression and improved therapeutic options may have all contributed to a milder PTLD phenotype and improved clinical outcomes.

KW - Epstein-Barr virus

KW - Histology

KW - Immunosuppression

KW - Liver transplantation

KW - Lymphoproliferative disease

KW - Outcome

UR - http://www.scopus.com/inward/record.url?scp=77952262867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952262867&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3046.2009.01258.x

DO - 10.1111/j.1399-3046.2009.01258.x

M3 - Article

VL - 14

SP - 504

EP - 511

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 4

ER -